Peptide Therapeutics Global Market Report 2024

The peptide therapeutics market size has grown rapidly in recent years. It will grow from $41.44 billion in 2023 to $45.66 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth observed in the historical period can be attributed to the increasing incidence of chronic diseases, a growing understanding of molecular biology, and expanding applications in oncology.

The peptide therapeutics market size is expected to see rapid growth in the next few years. It will grow to $68.83 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The anticipated growth in the forecast period can be attributed to the rising demand for personalized medicine, expanding applications in immunotherapy, advancements in peptide delivery systems, emerging peptide targets in infectious diseases, and an increasing focus on rare diseases. Major trends in the forecast period include technological advancements in peptide synthesis, growing investment and funding, an emphasis on peptide drug safety, market expansion in emerging economies, and the integration of artificial intelligence (AI).

The peptide therapeutics market is poised for growth, primarily fueled by the escalating prevalence of chronic diseases. Chronic diseases, characterized by their prolonged and often incurable nature, are on the rise, driven by factors such as increased tobacco product usage, suboptimal nutrition, physical inactivity, and excessive alcohol consumption. Despite being challenging to cure, chronic diseases can be managed and, in some cases, controlled. The utilization of peptide therapeutics plays a crucial role in both the prevention and treatment of certain chronic diseases. Notably, in January 2023, the National Library of Medicine, a US-based agency, reported a significant projection for the United States, indicating that the number of individuals aged 50 and older with at least one chronic condition is expected to surge by 99.5%, reaching 142.66 million by the year 2050. As a result, the anticipated increase in the prevalence of chronic diseases is set to be a key driver for the growth of the peptide therapeutics market throughout the forecast period.

The growth trajectory of the peptide therapeutics market is expected to be significantly influenced by the increasing size of the geriatric population. Defined as individuals aged 65 years and older, the geriatric population faces a higher prevalence of various health conditions. Peptide therapeutics play a pivotal role in managing and treating these conditions by targeting specific pathways associated with age-related diseases, improving bone density, and mitigating the risk of fractures. Notably, global demographic trends, as highlighted by the World Health Organization in October 2022, indicate that 1 in 6 people will be 60 years or older by 2030, with a projected doubling of this age group to 2.1 billion individuals by 2050. Further emphasizing the impact on specific regions, the UK Parliament's House of Commons Library reported in June 2021 that the senior population in the United Kingdom is expected to increase, constituting 24% of the total population (17.4 million people) by the year 2043. This demographic shift underscores the growing importance of peptide therapeutics in addressing the healthcare needs of the elderly. As a result, the rise in the geriatric population emerges as a significant driver propelling the growth of the peptide therapeutics market in the foreseeable future.

Major companies in the peptide therapeutics market are actively focused on introducing advanced solutions to gain a competitive edge, with a notable emphasis on innovations such as the cell culture process. The cell culture process involves growing cells outside of their natural environment under controlled conditions, which includes isolating cells of interest from living tissue and maintaining them. As an illustrative example, in June 2023, Evonik Industries AG, a German-based specialty chemicals company, launched cQrex KC. Positioned as a next-generation peptide for biopharma applications, cQrex KC is specifically designed for the cell culture process used in the manufacturing of biological drugs. It empowers cell culture process developers to optimize cystine supply and enhance cell culture productivity. Notably, cQrex KC contributes to the development of vaccines, viral vectors, and cell therapies, showcasing a commitment to advancing technologies that support crucial aspects of biopharmaceutical production.

Major companies in the peptide therapeutic market are strategically focused on introducing advanced solutions, with a particular emphasis on innovations such as peptide drug discovery, aiming to gain a competitive edge. Peptide drug discovery involves the process of identifying, designing, and developing therapeutic agents composed of short chains of amino acids, known as peptides. A case in point is Fujitsu Limited, a Japan-based information and communications technology equipment and services company, which, in May 2023, unveiled the Biodrug Design Accelerator. This platform is specifically designed to support peptide drug discovery scientists in pharmaceutical companies throughout the design, make, test, analyze (DMTA) cycles. Operating as a web-based solution, the Biodrug Design Accelerator provides assistance to peptide designers by offering visualization of amino acid sequences. This strategic move reflects a commitment to leveraging advanced technologies to enhance and streamline the peptide drug discovery process, ultimately contributing to advancements in therapeutic solutions.

In August 2021, Bayer, a pharmaceutical company headquartered in Germany, successfully completed the acquisition of Vividion Therapeutics for an undisclosed sum. This strategic move is poised to enhance Bayer's proficiency in small molecule therapeutics and open up new market opportunities. The integration of Vividion Therapeutics brings with it an advanced chemoproteomics platform, significantly bolstering Bayer's capabilities in drug discovery. Vividion Therapeutics, Inc., a biotechnology company based in the United States, specializes in pioneering highly selective small-molecule medicines, particularly targeting traditionally challenging therapeutic areas, thereby aligning with Bayer's commitment to transforming the landscape of human health.

Major companies operating in the peptide therapeutics market report are Pfizer Inc., Jhonson & Jhonson, Abbvie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk AS, Teva Pharmaceuticals Industries Ltd., Bachem Holding AG, PolyPeptide Laboratories BV, Arcus Biosciences Inc., Anaptys Bio Inc., Endoceutics Inc., Pepscan Therapeutics, Peptech Inc., Peptide Logic Inc., SELLAS Life Sciences Group, Ever Neuro Pharma GmbH, Zealand Pharma AG, PepGen Inc., Pepticom S.A., Arexis AB, Peptide Technologies Corporation, SynPeptide Inc., Peptimmune Inc., Merck & Co. Inc.

North America was the largest region in the peptide therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peptide therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary classifications of peptide therapeutics include generic and branded variants. Branded peptide therapeutics are drugs marketed under the brand names of major pharmaceutical companies that hold the patent for these medications. Branded drugs tend to be more costly than their generic counterparts, as they maintain a distinct brand identity. Peptide therapeutics can be administered through various routes such as parenteral, mucosal, oral, and transdermal. They find applications in treating a wide range of medical conditions, including cancer, cardiovascular diseases, central nervous system disorders, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology issues, respiratory disorders, and acromegaly.

The peptide therapeutics market research report is one of a series of new reports that provides peptide therapeutics market statistics, including peptide therapeutics industry global market size, regional shares, competitors with a peptide therapeutics market share, detailed peptide therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide therapeutics industry. This peptide therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide therapeutics market includes revenues earned by entities by creating drugs to treat a variety of diseases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.